“…For specifically identifying axon injury and loss, reduced NAA content measured by magnetic resonance spectroscopy (MRS) has been used (De Stefano et al, 1999;Aboul-Enein et al, 2010;Wood et al, 2012). However, inflammation can interfere with measuring myelin and axons because inflammation-induced tissue swelling falsely reduces the measured myelin water and NAA content (oedema water contains no NAA and dilutes myelin water fraction), MTR (oedema water exhibits no transfer effect while contributing to the total signal), and PET marker intensity (diluting marker density) (Schmierer et al, 2004;Stanisz et al, 2004;McCreary et al, 2009;Vavasour et al, 2011). Despite that DTI-derived axial diffusivity and radial diffusivity can concurrently quantify coexisting axonal injury and demyelination in some settings (Song et al, 2002(Song et al, , 2003(Song et al, , 2005, DTI becomes inaccurate in the presence of inflammation (Sun et al, 2006b;Lodygensky et al, 2010;Xie et al, 2010), tissue loss (Kim et al, 2007), crossing fibres (Wheeler-Kingshott and Cercignani, 2009), and CSF contamination (Karampinos et al, 2008;Cheng et al, 2011) and cannot measure the inflammatory components.…”